Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

PubWeight™: 1.98‹?› | Rank: Top 2%

🔗 View Article (PMC 3533246)

Published in J Hepatol on November 27, 2006


Sigal Kremer-Tal1, Goutham Narla, Yingbei Chen, Eldad Hod, Analisa DiFeo, Steven Yea, Ju-Seog Lee, Myron Schwartz, Swan N Thung, Isabel M Fiel, Michaela Banck, Eran Zimran, Snorri S Thorgeirsson, Vincenzo Mazzaferro, Jordi Bruix, John A Martignetti, Josep M Llovet, Scott L Friedman

Author Affiliations

1: Division of Liver Diseases and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.

Articles citing this

Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09

The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology (2008) 2.04

Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PLoS One (2012) 1.87

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci Transl Med (2013) 1.53

Krüppel-like factors in cancer. Nat Rev Cancer (2013) 1.32

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21

Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol (2008) 1.09

MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res (2014) 1.09

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (2011) 1.07

Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. Curr Genomics (2009) 1.01

Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS One (2010) 0.99

TGF-beta regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction. Biochem J (2009) 0.92

GSK3β phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene (2012) 0.88

Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy. Eur J Gastroenterol Hepatol (2009) 0.87

Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform. RNA Biol (2014) 0.87

Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences. World J Gastroenterol (2010) 0.86

Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. J Biol Chem (2011) 0.86

Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer (2008) 0.85

Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology (2012) 0.85

Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Lett (2010) 0.83

Kruppel-like factor 2 suppresses mammary carcinoma growth by regulating retinoic acid signaling. Oncotarget (2015) 0.83

Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury. Hepatology (2012) 0.81

A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer. Gastric Cancer (2011) 0.81

Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol (2016) 0.81

The impact of simvastatin on pulmonary effectors of Pseudomonas aeruginosa infection. PLoS One (2014) 0.79

A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination. Oncogene (2016) 0.79

Interaction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma. Oncotarget (2016) 0.78

Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. Mt Sinai J Med (2009) 0.77

AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells. PPAR Res (2012) 0.76

The Role of the 3' Untranslated Region in the Post-Transcriptional Regulation of KLF6 Gene Expression in Hepatocellular Carcinoma. Cancers (Basel) (2013) 0.76

Tumor suppressors in hepatocellular carcinoma: many are called, but few are chosen. J Hepatol (2007) 0.76

Platelet releasates promote the proliferation of hepatocellular carcinoma cells by suppressing the expression of KLF6. Sci Rep (2017) 0.75

KLF6SV1 siRNA inhibits proliferation of human lens epithelial cells. Mol Vis (2012) 0.75

Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury. Sci Rep (2017) 0.75

Articles cited by this

Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98

Hepatocellular carcinoma: recent trends in the United States. Gastroenterology (2004) 5.90

Terminology of nodular hepatocellular lesions. Hepatology (1995) 3.87

Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49

Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology (2001) 3.26

KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (2001) 3.22

Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12

Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol (2006) 2.97

KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer (2003) 2.70

Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42

Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol (2003) 2.36

Genetics of hepatocellular carcinoma. Semin Cancer Biol (2000) 2.30

Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29

Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res (2005) 2.08

A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02

Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol (1999) 1.87

Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. J Gastroenterol (1999) 1.70

Beta-catenin is temporally regulated during normal liver development. Gastroenterology (2004) 1.69

Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res (2005) 1.65

Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol (2000) 1.59

Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology (2004) 1.59

Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res (2001) 1.58

Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res (2004) 1.57

Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res (2004) 1.52

Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res (2006) 1.51

Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol (2003) 1.50

Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem (2005) 1.46

Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood (2005) 1.39

Genetic alterations of the KLF6 gene in gastric cancer. Oncogene (2005) 1.26

Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev (2003) 1.25

E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene (2006) 1.22

Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J Gastroenterol Hepatol (2002) 1.18

Genetic alterations and oncogenic pathways in hepatocellular carcinoma. Ann N Y Acad Sci (2002) 1.05

Overview of recent experimental studies on liver stem cells. Semin Liver Dis (2003) 1.04

Detection of albumin messenger RNA in hepatic and extrahepatic neoplasms. A marker of hepatocellular differentiation. Am J Surg Pathol (1997) 1.03

[Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas]. Ai Zheng (2002) 0.99

Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol (2002) 0.94

Developmentally regulated expression of KLF6 in the mouse cornea and lens. Invest Ophthalmol Vis Sci (2004) 0.89

[A candidate tumor suppressor gene mutated in primary hepatocellular carcinoma: kruppel-like factor 6]. Zhonghua Wai Ke Za Zhi (2004) 0.84

Engineering the hepatocyte differentiation-proliferation balance by acellular cadherin micropresentation. Tissue Eng (2004) 0.82

Up-regulation of E-cadherin and I-catenin in human hepatocellular carcinoma cell lines by sodium butyrate and interferon-alpha. In Vitro Cell Dev Biol Anim (2000) 0.82

Articles by these authors

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Hepatocellular carcinoma. Lancet (2003) 22.54

Hepatocellular carcinoma. Lancet (2012) 18.09

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68

Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet (2008) 5.66

Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27

Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95

Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17

miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71

Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63

CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62

Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49

A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 3.39

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18

Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04

Management of HCC. J Hepatol (2012) 3.03

Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00

Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev (2009) 2.98

Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev (2013) 2.96

HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest (2003) 2.89

Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89

Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85

Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82

Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79

New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology (2013) 2.76

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut (2012) 2.70

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66

The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl (2004) 2.65

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63

Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology (2010) 2.61